Evaluation of Atomoxetine on stuttering of children

Evaluation of Atomoxetine on stuttering of children in 4-12 years old refering to neurological clinic in Ardabil

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190717044247N1

Enrollment

100

Registered

2019-08-13

Start date

2019-09-23

Completion date

Unknown

Last updated

2019-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stuttering. stuttering

Interventions

Intervention 1: Intervention group: Including 50 patients who will be referred to the Pediatric Neurology Clinic for 2 months and randomly assigned to the Atomoxetine treatment group. This group will

Eligibility

Sex/Gender

All

Age

4 Years to 12 Years

Inclusion criteria

Inclusion criteria: All 4 to 12 year-old patients with stuttering.

Exclusion criteria

Exclusion criteria: Patients aged 12 to 4 years with stuttering with brain or evolutionary problems. Patients aged 4 to 12 years with stuttering do not go on a three-month follow-up to continue treatment. Patients aged 4 to 12 years with stutter, who are treated with a drug other than atomextin.

Design outcomes

Primary

Measure	Time frame
Stuttering severity. Timepoint: Beginning of intervention and end of the 3 month period. Method of measurement: Severity Measurement Tool SSI4.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAkram Motamedi

Ardabil University of Medical Sciences

amot314@yahoo.com+98 45 3325 2251

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026